Dalsgarð 2004.

Methods	BUPROPION Randomized controlled trial Setting: 5 hospitals, Denmark Recruitment: hospital staff
Participants	335 smokers incl physicians, nurses, other hospital service and admin staff, >= 10 CPD, no history of MDD; 75% F, av. age 43, av. CPD 19
Interventions	1. Bupropion 300 mg/day for 7 weeks 2. Placebo Both arms: motivational support around TQD, at w3 & 7, and at 12w follow up
Outcomes	Abstinence at 6m (prolonged from w4) Validation: CO < 10 ppm
Notes	Funding: GlaxoSmithKline
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization was computer generated and blinded.
Allocation concealment (selection bias)	Low risk	Allocation was double‐blinded and bupropion and placebo tablets were identical in form and number.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Double‐blind" Clear that participants were blinded but unclear if all staff were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	32% of the bupropion group and 43% the placebo group discontinued treatment, included in analysis.